Pledge Therapeutics
Biotechnology Research
Canton, MA 6,031 followers
Harnessing advanced biophysical & structural technologies to design transformative medicines against challenging targets
About us
Pledge Therapeutics efforts have given rise to a constellation of exciting discoveries, spanning from early drug hits to preclinical candidates. Our success is based on the rapid translation of clinical and disease insights into target identification and development of novel drug molecules. At the core of our effort is the integration of structural and biophysical knowledge of disease targets to accelerate the pace and success of drug development.
- Website
-
https://pledge-tx.com
External link for Pledge Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Canton, MA
- Type
- Privately Held
Locations
-
Primary
Get directions
Canton, MA 02021, US
-
Get directions
Gaston Geenslaan 1
Leuven , 3001, BE
Employees at Pledge Therapeutics
Updates
-
Pledge Therapeutics and our CEO Dr. Ali Munawar are immersed in the Immuno-Oncology Summit Europe 2024 in London. With our groundbreaking advancements in our Immuno-Oncology pipeline, we look forward to lively breakout discussions, networking opportunities, and connecting with global leaders in the Immuno-Oncology space. #ImmunoOncology #IOSummitUK #DrugDiscovery #Biopharma Our Immuno-Oncology programs reside under Conformation-X Therapeutics a company affiliated with Pledge Therapeutics. https://lnkd.in/dgE7-xS
-
We are thrilled to announce that Conformation-X Therapeutics, affiliated with Pledge Therapeutics, has emerged from stealth mode, securing an additional $3.65 million in funding. This brings our total raised to over $13.5 million since inception. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts. Read more: https://lnkd.in/erAF-B9c Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
businesswire.com
-
Tremendous news from Orthogon Therapeutics, Pledge Therapeutics antiviral arm: We are celebrating a major technical milestone and securing an additional $6M for our pioneering drug to combat #BKvirus! Our lead molecule completed acute toxicity studies, unlocking $3M from dedicated healthcare investors, wrapping up a $6M financing over the past year, bringing the total raised to $18.5M! A groundbreaking journey lies ahead of us, and we're thrilled to forge ahead in search of a transformative solution for kidney transplant patients: #BKvirus is a type of polyomavirus that causes a lifelong, persistent, and often asymptomatic infection in over 80% of healthy adults. In transplant patients, nearly half experience BK virus reactivation in their kidneys, which can lead to serious complications and loss of the transplanted organ. #AntiviralTherapeutics #MedicalInnovation #BKvirusTreatment #HealthcareAdvancements https://lnkd.in/enEXPeKF
Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus
businesswire.com